Lake Street Rates Kazia Therapeutics (KZIA) buy, $32 Price Target
Lake Street reaffirms its buy rating on Kazia Therapeutics, setting a price target of $32, a 127.27% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
Lake Street rated Kazia Therapeutics Limited ($KZIA) "buy" with a $32 price target on June 11, 2026.
Since the rating, $KZIA is up 10.5% after 1 week, up 8.4% after 1 month and down 42.2% to date (from the $12.54 close on Jun 11, 2026).
KZIA
Kazia Therapeutics Limited
Key Points
- Lake Street reiterated its buy rating on Kazia Therapeutics Limited (KZIA) with a target price of $32, while shares sit at $14.08.
- Lake Street's $32 price target implies 127.27% upside from Kazia Therapeutics Limited's ($KZIA) current $14.08 share price.
- The stock has recently traded well above its 50-day moving average of $12.83, indicating positive momentum.
- Analysts currently have a consensus recommendation of strong buy for Kazia, with a mean target price of about $28.8.
Get $KZIA trade alerts by text
We text you when insiders, Congress or big funds trade $KZIA. Free.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Kazia Therapeutics Limited alert may contain errors. Disclosures
Rating Reiteration from Lake Street
Lake Street has reiterated its buy rating on Kazia Therapeutics Limited (KZIA) with a price target of $32 in a report dated June 11, 2026. The stock closed at $14.08 on the preceding Friday, indicating a significant upside based on the new target. This latest assessment aligns with Lake Street's long-term view of the company's potential in the biotechnology sector.
Analysts Set New Price Targets
Kazia Therapeutics has garnered attention from various analysts recently. On September 10, 2026, BTIG reiterated its buy rating with a target of $40. Earlier, on September 1, BTIG maintained its buy rating while raising its target from $34 to $40. Canaccord Genuity also joined the positive sentiment, initiating coverage with a buy rating and a target of $29 on August 13. Overall, the consensus among analysts is a strong buy, with a mean price target of approximately $28.8.
Stock Performance Insights
Kazia Therapeutics has been performing notably well, especially compared to its 50-day moving average of $12.83. The stock recently reached a 52-week high of $17.40, suggesting a strong upward trajectory. Given its current trading price of $14.08, the shares are still below the latest analyst targets, which could signify an attractive opportunity for investors as the company progresses with its clinical trials.
$KZIA price target
Kazia Therapeutics Limited daily closes and this analyst's $32 target. Not advice.
Recent Insider Activity
In a separate update, Chief Financial Officer James Levine purchased 200,000 shares on June 19, 2026. This transaction occurred at an average price of $0.00, indicating it might be part of an incentive or compensation package rather than a market purchase. This insider buying could reflect confidence in the company's future.
About Kazia Therapeutics
Kazia Therapeutics Limited focuses on developing innovative treatments in oncology. Based in Sydney, Australia, the company is working on its lead candidate, paxalisib, which is in advanced clinical trials for glioblastoma and other brain cancers. Their pipeline includes additional promising therapies aimed at various tumor types, underscoring their commitment to addressing critical health challenges.
What’s Next for Kazia?
Kazia Therapeutics is scheduled to report earnings on May 28, 2025. Investors and analysts will be looking for updates on their clinical trials and overall business progress. Keep in mind that the recent 13F filings often reflect historical positions, and current holdings may differ. The reiteration of buy ratings and optimistic price targets position Kazia favorably as it moves forward in its business strategy.
Related Filing Alerts
Source: Lake Street's rating change on $KZIA (Jun 11, 2026). Written by software, not financial advice. How we make alerts